17 material Form 8-K filings that 16 companies we cover made with the SEC in May 2023, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
EUDA Health Holdings issued 2,317,606 restricted shares on May 16, 2023, to settle debts owed to a major shareholder, its CEO and related companies, and converted a $700,000 note into 700,000 shares. Between May 16 and May 22, 2023, it also sold 940,000 shares at $1.00 each to eight accredited investors for $940,000, which adds to the outstanding share count.
1,617,606 shares issued May 16, 2023, under five settlement agreements, including 850,306 shares to CEO Kelvin Chen to satisfy a $850,306 claim.
700,000 shares issued May 16, 2023, after James Tan converted a $700,000 note at $1.00 per share.
940,000 shares sold at $1.00 each, for $940,000, to eight accredited investors between May 16 and May 22, 2023.
None of the shares are registered under the Securities Act; the company agreed to register resale of the placement shares under registration rights agreements.
On May 21, 2023, Krystal Biotech agreed to sell 1,729,729 shares of common stock to institutional investors at $92.50 per share, for an aggregate purchase price of approximately $160 million before offering expenses. The company plans to use the proceeds for commercialization of VYJUVEK, its clinical pipeline, business development, and working capital, and expects the sale to close on May 22, 2023. The new shares add to the company's outstanding share count, which dilutes existing shareholders, while the company says the funds should support operations through the end of 2026.
1,729,729 shares of common stock to be sold at $92.50 per share, for approximately $160 million in gross proceeds before offering-related expenses
Agreement dated May 21, 2023; closing expected May 22, 2023, subject to customary conditions
Financing led by Avoro Capital Advisors and Redmile Group, LLC, with participation from Braidwell LP and Frazier Life Sciences
Company agreed to file a registration statement for resale of the shares within 60 days of closing
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.